Amber Afzal, MD
Hematology · Saint Louis, MONPI 1831539808
Payments from drug & device makers
What this record shows
This record is dominated by education: $102 of the $127 with a category attached, or 80.2%. 3 manufacturers reported payments, led by Incyte Corporation at 56.7% of the total. Reporting peaked in 2019 at $72 and has fallen 65.1% since, to $25 in 2025. That places this record below the midpoint for hematology clinicians in MO, where the typical reported total is $354.
Across 4 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$72
- E.r. Squibb & Sons, L.L.C.$30
- Sobi, Inc$25
Across 4 payments — averaging $5197.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$21K
What the payments were for
- Food & beverage$2520%
- Education$10280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $72 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Sobi, Inc | 1 | $25 |
How this compares
$127 in reported general payments places this provider in the 40th percentile of 27 hematology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 55 | $843,202 |
| PromactaEltrombopag Olamine | 50 | $638,760 |
| PomalystPomalidomide | 12 | $268,475 |
| BrukinsaZanubrutinib | 24 | $238,868 |
| VenclextaVenetoclax | 11 | $172,232 |
| RevlimidLenalidomide | 13 | $144,687 |
| EliquisApixaban | 88 | $78,248 |
| XareltoRivaroxaban | 78 | $60,597 |
| SiklosHydroxyurea | 12 | $21,490 |
| Anagrelide Hcl | 11 | $2,641 |
| Hydroxyurea | 95 | $2,173 |
| Warfarin Sodium | 127 | $1,105 |
| Dexamethasone | 21 | $189 |
| Acyclovir | 11 | $85 |
| Gabapentin | 13 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $30 | $268,47512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 27 hematology providers in Missouri.
Other hematology in Saint Louis
- Morey BlinderSaint Louis$235K
- Stephen OhSaint Louis$143K
- Elaine MajerusSaint Louis$111K
- Govind BhagatSaint Louis$67K
- Amy ZhouSaint Louis$18K
- Shaun HansonSaint Louis$15K
- Stuart KornfeldSaint Louis$4K
- Joshua SinerSaint Louis$1K
- Andrew YoungSaint Louis$789
- Kristen SanfilippoSaint Louis$354
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.